Cargando…

Correlation of transforming growth factor-β1 and tumour necrosis factor levels with left ventricular function in Chagas disease

BACKGROUND: Transforming growth factor β1 (TGF-β1) and tumour necrosis factor (TNF) have been implicated in Chagas disease pathophysiology and may correlate with left ventricular (LV) function. OBJECTIVES: We determined whether TGF-β1 and TNF serum levels correlate with LV systolic and diastolic fun...

Descripción completa

Detalles Bibliográficos
Autores principales:	Curvo, Eduardo OV, Ferreira, Roberto R, Madeira, Fabiana S, Alves, Gabriel F, Chambela, Mayara C, Mendes, Veronica G, Sangenis, Luiz Henrique C, Waghabi, Mariana C, Saraiva, Roberto M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Instituto Oswaldo Cruz, Ministério da Saúde 2018
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5851032/ https://www.ncbi.nlm.nih.gov/pubmed/29513876 http://dx.doi.org/10.1590/0074-02760170440

Ejemplares similares

TGF-β Polymorphisms Are a Risk Factor for Chagas Disease
por: Ferreira, Roberto Rodrigues, et al.
Publicado: (2018)

Impact of pharmaceutical care on the quality of life of patients with Chagas disease and heart failure: randomized clinical trial
por: da Silva, Gilberto M Sperandio, et al.
Publicado: (2012)

Biomarkers and Echocardiographic Predictors of Cardiovascular Outcome in Patients With Chronic Chagas Disease
por: Mendes, Veronica G., et al.
Publicado: (2023)

Two-dimensional strain derived parameters provide independent predictors of progression to Chagas cardiomyopathy and mortality in patients with Chagas disease
por: Saraiva, Roberto M., et al.
Publicado: (2022)

Chagas heart disease: An overview of diagnosis, manifestations, treatment, and care
por: Saraiva, Roberto M, et al.
Publicado: (2021)

Ageing with Chagas disease: an overview of an urban Brazilian cohort in Rio de Janeiro
por: Vizzoni, Alexandre Gomes, et al.
Publicado: (2018)

The Search for Biomarkers and Treatments in Chagas Disease: Insights From TGF-Beta Studies and Immunogenetics
por: Ferreira, Roberto Rodrigues, et al.
Publicado: (2022)

Transforming growth factor-ß as a therapeutic target for the cardiac damage of Chagas disease
por: Waghabi, Mariana Caldas, et al.
Publicado: (2022)

Prevalence of metabolic syndrome and associated factors among patients with chronic Chagas disease
por: Xavier, Isis Gabrielli Gomes, et al.
Publicado: (2021)

Home-based exercise program in the indeterminate form of Chagas disease (PEDI-CHAGAS study): A study protocol for a randomized clinical trial
por: Mediano, Mauro F. F., et al.
Publicado: (2023)

Corrigendum: Home-based exercise program in the indeterminate form of Chagas disease (PEDI-CHAGAS study): a study protocol for a randomized clinical trial
por: Mediano, Mauro F. F., et al.
Publicado: (2023)

Scrutinizing the Biomarkers for the Neglected Chagas Disease: How Remarkable!
por: Pinho, Rosa T., et al.
Publicado: (2016)

Selenium, TGF-Beta and Infectious Endemic Cardiopathy: Lessons from Benchwork to Clinical Application in Chagas Disease
por: Araujo-Jorge, Tania C., et al.
Publicado: (2022)

Benznidazole decreases the risk of chronic Chagas disease progression and cardiovascular events: A long-term follow up study
por: Hasslocher-Moreno, Alejandro M., et al.
Publicado: (2020)

Association between Trypanosoma cruzi DTU TcII and chronic Chagas disease clinical presentation and outcome in an urban cohort in Brazil
por: Nielebock, Marco Antonio Prates, et al.
Publicado: (2020)

Autochthonous transmission of Chagas disease in Rio de Janeiro State, Brazil: a clinical and eco-epidemiological study
por: Sangenis, Luiz Henrique Conde, et al.
Publicado: (2015)

Temporal changes in the clinical-epidemiological profile of patients with Chagas disease at a referral center in Brazil
por: Hasslocher-Moreno, Alejandro Marcel, et al.
Publicado: (2021)

FIRST REPORT OF ACUTE CHAGAS DISEASE BY VECTOR TRANSMISSION IN RIO DE JANEIRO STATE, BRAZIL
por: SANGENIS, Luiz Henrique Conde, et al.
Publicado: (2015)

Nox2 and Nox4 mediate tumour necrosis factor-α-induced ventricular remodelling in mice
por: Moe, K T, et al.
Publicado: (2011)

Oral Administration of GW788388, an Inhibitor of Transforming Growth Factor Beta Signaling, Prevents Heart Fibrosis in Chagas Disease
por: de Oliveira, Fabiane L., et al.
Publicado: (2012)

In Chagas disease, transforming growth factor beta neutralization reduces Trypanosoma cruzi infection and improves cardiac performance
por: Ferreira, Roberto Rodrigues, et al.
Publicado: (2022)

Progression Rate from the Indeterminate Form to the Cardiac Form in Patients with Chronic Chagas Disease: Twenty-Two-Year Follow-Up in a Brazilian Urban Cohort
por: Hasslocher-Moreno, Alejandro Marcel, et al.
Publicado: (2020)

Severity of chronic experimental Chagas' heart disease parallels tumour necrosis factor and nitric oxide levels in the serum: models of mild and severe disease
por: Pereira, Isabela Resende, et al.
Publicado: (2014)

Tumour necrosis factor in man: clinical and biological observations.
por: Selby, P., et al.
Publicado: (1987)

Effects on tumour microcirculation in mice of misonidazole and tumour necrosis factor plus hyperthermia.
por: Fujimoto, S., et al.
Publicado: (1992)

The comparative effectiveness of abatacept versus anti-tumour necrosis factor switching for rheumatoid arthritis patients previously treated with an anti-tumour necrosis factor
por: Harrold, Leslie R, et al.
Publicado: (2015)

Tumour-infiltrating lymphocytes bear the 75 kDa tumour necrosis factor receptor.
por: Trentin, L., et al.
Publicado: (1995)

ELISA versus PCR for diagnosis of chronic Chagas disease: systematic review and meta-analysis
por: Brasil, Pedro EAA, et al.
Publicado: (2010)

Right ventricular dysfunction in Chagas' Cardiomyopathy. Primary involvement or a resonant manifestation of Left ventricular dysfunction?
por: Moreira, Henrique T, et al.
Publicado: (2014)

Relationship between Fibrosis and Ventricular Arrhythmias in Chagas Heart Disease Without Ventricular Dysfunction
por: Tassi, Eduardo Marinho, et al.
Publicado: (2014)

Carnitine and congeners as regulators of tumour necrosis factor
por: De Simone, Claudio, et al.
Publicado: (1993)

Tumour necrosis factor-α in nasal allergy
por: Hisamatsu, K., et al.
Publicado: (1995)

Tumour necrosis factor signalling in health and disease
por: Holbrook, Jonathan, et al.
Publicado: (2019)

Tumour necrosis factor production and natural killer cell activity in peripheral blood during treatment with recombinant tumour necrosis factor.
por: MÃ¤nnel, D. N., et al.
Publicado: (1989)

Effects of Selenium treatment on cardiac function in Chagas heart disease: Results from the STCC randomized Trial
por: Holanda, Marcelo T., et al.
Publicado: (2021)

Enhanced anti-tumour activity of carmustine (BCNU) with tumour necrosis factor in vitro and in vivo.
por: Jones, A. L., et al.
Publicado: (1990)

Tumour-necrosis factor from the rabbit. IV. Purification and chemical characterization.
por: Matthews, N., et al.
Publicado: (1980)

MICA and KIR: Immunogenetic Factors Influencing Left Ventricular Systolic Dysfunction and Digestive Clinical Form of Chronic Chagas Disease
por: Ayo, Christiane Maria, et al.
Publicado: (2021)

The neutrophil migration induced by tumour necrosis factor alpha in mice is unaffected by glucocorticoids
por: Cecilio, C. A., et al.
Publicado: (1997)

Paradoxical Roles of Tumour Necrosis Factor-Alpha in Prostate Cancer Biology
por: Tse, Brian W. C., et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_ruv95r737k83366ajsvcogs2e8